Ignite Creation Date:
2024-05-06 @ 7:55 PM
Last Modification Date:
2024-10-26 @ 3:17 PM
Study NCT ID:
NCT06189495
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-01-03
First Post:
2023-11-13
Brief Title:
A Randomized Double-blind Placebo-controlled Phase II Clinical Study to Evaluate the Safety Tolerability Efficacy and Pharmacokinetic Profile of Genakumab Injection in Patients With Connective Tissue Disease-associated Interstitial Lung Disease
Sponsor:
Changchun GeneScience Pharmaceutical Co Ltd
Organization:
Changchun GeneScience Pharmaceutical Co Ltd
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-12-30
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-03-31
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-10-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-11-13
First Submit QC Date:
December 19 2023
Study First Post Date:
2024-01-03
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-12-19
Last Update Post Date:
2024-01-03
Last Update Post Date Type:
ACTUAL